Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialResearch in context

Summary: Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity and phagocytosis compared to rituximab. Our aim was t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ashwath Gurumurthi, Collin K. Chin, Lei Feng, Nathan H. Fowler, Paolo Strati, Fredrick B. Hagemeister, Luis E. Fayad, Jason R. Westin, Chizobam Obi, Janine Arafat, Ranjit Nair, Raphael E. Steiner, Sattva S. Neelapu, Christopher R. Flowers, Loretta J. Nastoupil
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-08-01
Edice:	EClinicalMedicine
Témata:	Follicular lymphoma Lenalidomide Obinutuzumab Relapsed
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589537024003262
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!